BioCentury | Aug 8, 2013
Distillery Therapeutics

Indication: Cancer

...of adrenergic and muscarinic inhibitors in the indication. GlaxoSmithKline plc markets the ADRB2 antagonist Coreg carvedilol...
BioCentury | Jun 10, 2013
Clinical News

RHB-101 regulatory update

...to compare the pharmacokinetics of RHB-101, a once-daily, controlled-release formulation of carvedilol, to Coreg CR carvedilol...
...RHB-101 from Egalet under a November 2009 deal. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets Coreg...
...treat chronic heart failure, hypertension and left ventricular dysfunction following myocardial infarction in stable patients. Carvedilol...
BioCentury | Mar 25, 2013
Clinical News

Carvedilol regulatory update

...timeline for an MAA or U.S. submission. The product is a once-daily, controlled-release formulation of carvedilol...
...deal. Egalet Ltd. , Vaerlose, Denmark RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL), Ramat-Gan, Israel Product: Carvedilol...
BioCentury | Jul 21, 2011
Distillery Therapeutics

Indication: Cardiovascular disease

...arrhythmia. A compound with SOICR blocking activity was synthesized based on the parent compound Coreg carvedilol...
...determining whether the analogs have other actions in addition to anti-SOICR activity. GlaxoSmithKline plc markets Coreg...
...indications. Egalet A/S and partner RedHill BioPharma Ltd. are developing EG-P042, a prolonged-release formulation of carvedilol...
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...tachycardia BenproperineA Information not available Information not available Cough Calcipotriol Information not available Generic Psoriasis Carvedilol...
BioCentury | Mar 30, 2009
Company News

Flamel, GlaxoSmithKline deal

...Coreg carvedilol to treat heart failure. The payment was triggered by an undisclosed sales milestone. Coreg...
BioCentury | Feb 9, 2009
Finance

Ebb & Flow

...development of Coreg CR in combination with an undisclosed angiotensin-converting enzyme (ACE) inhibitor for hypertension. Coreg...
BioCentury | Feb 9, 2009
Clinical News

Coreg CR and ACE inhibitor: Development discontinued

...GSK terminated development of a fixed-dose combination of Coreg CR and an undisclosed angiotensin-converting enzyme (ACE...
...an undisclosed angiotensin-converting enzyme (ACE) inhibitor, which was in Phase III testing to treat hypertension. Coreg...
...NYSE:GSK), London, U.K. Product: Coreg CR and ACE inhibitor Business: Cardiovascular Molecular target: NA Description: Coreg...
BioCentury | Feb 6, 2009
Company News

GSK expands restructuring, reports earnings

...other tyrosine kinases is expected this quarter. The company also said it terminated development of Coreg...
...an undisclosed angiotensin-converting enzyme (ACE) inhibitor that was in Phase III testing to treat hypertension. Coreg...
BioCentury | Sep 29, 2008
Product Development

BEST foot forward

...marketed products like Coreg carvedilol from GlaxoSmithKline plc and generic beta blockers like metoprolol. The Coreg...
Items per page:
1 - 10 of 65